α-Isocyanato-essigsaeure | 65461-92-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: α-Isocyanato-essigsaeure
• 英文别名: glycine isocyanate；Carboxymethylisocyanate；2-isocyanatoacetic acid
• CAS: 65461-92-9
• 化学式: C₃H₃NO₃
• mdl: MFCD19228546
• 分子量: 101.062
• InChiKey: YSTZOIZIUXECPH-UHFFFAOYSA-N

物化性质

• 沸点：
  222.1±23.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  66.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-benzyloxycarbonyl-S-benzylcysteinyl-glycine 、 α-Isocyanato-essigsaeure 生成 N-benzyloxycarbonyl-S-benzylcysteinyl-glycyl-glycine ethyl ester
  参考文献：
  名称：

  Lautsch et al., Osterreichische Chemiker-Zeitung, 1957, vol. 58, p. 33,37

  摘要：

  DOI：
• 作为产物：
  描述：

  三光气 、 甘氨酸叔丁酯盐酸盐 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以52%的产率得到α-Isocyanato-essigsaeure
  参考文献：
  名称：

  [EN] PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS
  [FR] ANALOGUES DE PHOSPHONATE DE COMPOSES INHIBITEURS DE L'INTEGRASE DU VIH

  摘要：

  公开号：

  WO2005117904A3

文献信息

• Integrin antagonists useful as anticancer agents
  申请人：Bloxham Jason

  公开号：US20060116383A1

  公开（公告）日：2006-06-01

  The invention relates to compounds of the Formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X 2 , X 4 , X 5 and X 1 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of Formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of Formula 1.

  该发明涉及公式1的化合物，以及其药用可接受的盐和溶剂化合物，其中A、X2、X4、X5和X1的定义如本文所述。该发明还涉及通过给予公式1的化合物来治疗哺乳动物体内的异常细胞增长的方法，以及用于治疗这类疾病的含有公式1化合物的药物组合物。
• Composition for increasing the anti-cancer activity of an anti-cancer
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US05155113A1

  公开（公告）日：1992-10-13

  A composition for increasing the anti-cancer activity of an anti-cancer compound selected from among 5-fluorouracil and a compound capable of producing 5-fluorouracil in vivo, the composition comprising an effective amount of a pyridine derivative represented by the formula ##STR1## wherein R.sup.1 is hydroxy or acyloxy, R.sup.2 and R.sup.4 are each hydrogen, halogen, amino, carboxyl, carbamoyl, cyano, nitro, lower alkyl, lower alkenyl or lower alkoxycarbonyl, R.sup.3 and R.sup.5 are each hydrogen, hydroxy or acyloxy; when at least one or R.sup.1, R.sup.3 and R.sup.5 is hydroxy, the structure of 1-position on the pyridine ring can be ##STR2## due to the keto-enol tautomerism, said hydrogen attached to nitrogen being optionally substituted with a substituent selected from the group consisting of lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, phthalidyl, carbamoyl, lower alkoxycarbonyl-lower alkylcarbamoyl, phenyl-lower alkoxy-lower alkyl, phenylcarbamoyl which may have a substituent on the phenyl ring, lower alkylcarbamoyl, carboxy-lower alkylcarbamoyl, lower alkylthio-lower alkyl and lower alkenyl, provided that the compound having the following formula is excluded, ##STR3## wherein .alpha. is hydrogen, lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, lower alkylcarbamoyl, lower alkylthio-lower alkyl or lower alkenyl.

  一种用于增强抗癌化合物的抗癌活性的组合物，所述抗癌化合物从5-氟尿嘧啶和能够在体内产生5-氟尿嘧啶的化合物中选择，所述组合物包括有效量的由公式表示的吡啶衍生物：##STR1## 其中R.sup.1是羟基或酰氧基，R.sup.2和R.sup.4分别是氢、卤素、氨基、羧基、氨基甲酰、氰基、硝基、低碳基、低烯基或低烷氧羰基，R.sup.3和R.sup.5分别是氢、羟基或酰氧基；当R.sup.1、R.sup.3和R.sup.5中至少有一个是羟基时，吡啶环上1位的结构可以由于酮-烯醇互变异构而是##STR2## 所述氢原子连接到氮上可以选择地被下列取自所述群的取代基所取代：低碳基、四氢呋喃基、四氢吡喃基、低烷氧基-低碳基、邻苯二甲酰基、氨基甲酰-低碳基氧羰基-低烷氧基-低碳基、苯基-低烷氧基-低碳基、苯基甲酰基，所述苯环上可能有取代基，低碳基甲酰基、羧基-低碳基甲酰基、低硫基-低烷基和低烯基；但是，具有以下公式的化合物被排除：##STR3## 其中α是氢、低碳基、四氢呋喃基、四氢吡喃基、低烷氧基甲酰基、低碳基甲酰基、低硫基-低烷基或低烯基。
• 10.1021/acsmedchemlett.4c00183
  作者：Schneider, Nicholas O.、Gilreath, Kendra、Henriksen, Niel M.、Donaldson, William A.、Chaudhury, Subhabrata、St. Maurice, Martin

  DOI：10.1021/acsmedchemlett.4c00183

  日期：——

  noncompetitive with respect to ATP. This class of inhibitors appears to be selective for PC. Inhibitors in the IZT series do not inhibit the metalloenzymes human carbonic anhydrase II and matrix metalloprotease-12, and they do not inhibit the related biotin-dependent enzyme, guanidine carboxylase. Altogether, IZTs offer promise as PC inhibitors with potential downstream applications in cellular and

  通过计算机筛选方法，取代咪唑烷三酮 (IZT) 已被鉴定为丙酮酸羧化酶 (PC) 的有效抑制剂。 2-(2,4,5-三氧代-3-取代的咪唑啉-1-基)乙酸烷基酯 ( 6i – 6r ) 是该系列中最有效的，IC 50值在 3 至 12 μM 之间，并且多个 IZT 表现出高穿过人工膜的被动渗透性。 IZT 是丙酮酸的混合型抑制剂，并且对于 ATP 是非竞争性的。这类抑制剂似乎对 PC 具有选择性。 IZT 系列抑制剂不抑制金属酶人碳酸酐酶 II 和基质金属蛋白酶 12，也不抑制相关的生物素依赖性酶胍羧化酶。总而言之，IZT 作为 PC 抑制剂具有在细胞和体内系统中潜在下游应用的前景。
• Sofia, Michael J., Medicinal Chemistry Research, 1998, vol. 8, # 7-8, p. 362 - 378
  作者：Sofia, Michael J.

  DOI：——

  日期：——
• Identifying structural features on 1,1-diphenyl-hexahydro-oxazolo[3,4-a]pyrazin-3-ones critical for Neuropeptide S antagonist activity
  作者：Yanan Zhang、Brian P. Gilmour、Hernán A. Navarro、Scott P. Runyon

  DOI：10.1016/j.bmcl.2008.05.098

  日期：2008.7

  A series of 7-substituted 1,1-diphenyl-hexahydro-oxazolo[3,4-a]pyrazin-3-ones were synthesized and tested for Neuropeptide S (NPS) antagonist activity. A concise synthetic route was developed, which features a DMAP catalyzed carbamate formation. 4-Fluorobenzyl urea (1c) and benzyl urea (1d) were identified as the most potent antagonists among the compounds examined. Structure-activity relationships (SARs) demonstrate that a 7-position urea functionality is required for potent antagonist activity and alkylation of the urea nitrogen (1e) or replacement with carbon or oxygen (5a) results in reduced potency. In addition, compounds with alpha-methyl substitution (1b) or elongated alkyl chains (1h and 1j) had reduced potency, indicating a limited tolerance for 7-position substituents. (c) 2008 Elsevier Ltd. All rights reserved.